With the coronavirus (COVID-19) epidemic Vaccination works, one of our most important trump cards in the fight, continue without slowing down. Developed by Pfizer-BioNTech and fully approved by the FDA Comirnaty including the vaccine Moderna, Sputnik-V, Sinovac Vaccines developed with different technologies such as
Inactivated coronavirus vaccine developed by the Ministry of Health and Erciyes University Turkovac, was opened to the access of citizens after receiving emergency use approval. Anyone who has the first and second dose of vaccine can optionally receive the reminder dose with Turkovac. Developed with a different technology from Turkovac from the new domestic vaccine The good news has come.
Phase-3 results of Turkovac vaccine announced
Data on Phase-3 studies of the Turkovac vaccine were shared. Here are the effectiveness analyzes made on 1182 volunteers…
A new domestic vaccine is being developed with the adenovirus method
According to the news of Hürriyet, the local research institute led by Ankara University Cancer Research Institute adenovirus method is developed. According to the information shared by the Ministry of Health, with viral vector (adenovirus) vaccines; It is aimed to create immunity in humans by supporting a virus that causes flu-like illness with the Coronavirus protein after genetic intervention.
The studies of the domestic vaccine, which is stated to be administered through the mouth and nose, started on March 17, 2020. After production in a laboratory environment successfully completed animal experiments Approval of the Ministry of Health was applied to start the clinical trial of the vaccine. However, the application was rejected as production was required in a factory environment for human experiments.
Thereupon, an agreement was reached with a pharmaceutical factory in Istanbul. After the vaccine was produced, the approval of the Ministry of Health was applied for the clinical study again, and this time the ministry got permission.
Phase-1 study of the vaccine has started
Speaking about the study that started at Ankara City Hospital Clinical Research Center, Institute Director Prof. Dr. Hakan Akbulut, vaccinate Phase-1 process started conveyed the information. Akbulut is currently one of the most common and used vaccines in the world. mRNA, inactive and similar adenoviral vector based He said there are vaccines.
Saying that the vaccine they developed is an innovative and high-tech adenoviral vector vaccine, Hakan Akbulut said, “It is an important event for us that such a vaccine can be made in our country and brought to this stage.” used the phrase. Noting that a total of 4 domestic vaccines have been developed together with Turkovac, Akbulut stated that they expect the new vaccine to be effective against all variants.
One dose is expected to be effective for 2 years
prof. Dr. Hakan Akbulut said that they expect the vaccine, whose Phase-1 study has started, to create long-term immunity. “Instead of having to do a repeat dose every 3-4 months effective for an average of 2 years after vaccination We designed it”, Akbulut continued in his statement. “But of course, we can say all this as design right now. We will see the real study together after we do the clinical study.” said.
Hakan Akbulut shared the information that with the developed adenoviral vector-based vaccine, an immunity will be created in the structures in the oral and nasal cavities. Stating that oral and nasal administration will start from Phase-2, Akbulut said that he wanted to volunteer. The condition of not having coronavirus and not being vaccinated He said he was looking for.